Clinical Trial Update: Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated tolerability and pharmacokinetics of roflumilast at 250 μg and 500 μg as add-on therapy to standard COPD treatment in patients with se…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED | Results posted: 2017-03-14